Literature DB >> 19884466

Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure.

Harm J Bogaard1, Ramesh Natarajan, Scott C Henderson, Carlin S Long, Donatas Kraskauskas, Lisa Smithson, Ramzi Ockaili, Joe M McCord, Norbert F Voelkel.   

Abstract

BACKGROUND: The most important determinant of longevity in pulmonary arterial hypertension is right ventricular (RV) function, but in contrast to experimental work elucidating the pathobiology of left ventricular failure, there is a paucity of data on the cellular and molecular mechanisms of RV failure. METHODS AND
RESULTS: A mechanical animal model of chronic progressive RV pressure overload (pulmonary artery banding, not associated with structural alterations of the lung circulation) was compared with an established model of angioproliferative pulmonary hypertension associated with fatal RV failure. Isolated RV pressure overload induced RV hypertrophy without failure, whereas in the context of angioproliferative pulmonary hypertension, RV failure developed that was associated with myocardial apoptosis, fibrosis, a decreased RV capillary density, and a decreased vascular endothelial growth factor mRNA and protein expression despite increased nuclear stabilization of hypoxia-induced factor-1alpha. Induction of myocardial nuclear factor E2-related factor 2 and heme-oxygenase 1 with a dietary supplement (Protandim) prevented fibrosis and capillary loss and preserved RV function despite continuing pressure overload.
CONCLUSIONS: These data brought into question the commonly held concept that RV failure associated with pulmonary hypertension is due strictly to the increased RV afterload.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19884466     DOI: 10.1161/CIRCULATIONAHA.109.883843

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  201 in total

1.  Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans.

Authors:  Harm J Bogaard; Shiro Mizuno; Christophe Guignabert; Aysar A Al Hussaini; Daniela Farkas; Gerrina Ruiter; Donatas Kraskauskas; Elie Fadel; Jeremy C Allegood; Marc Humbert; Anton Vonk Noordegraaf; Sarah Spiegel; Laszlo Farkas; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2011-12-28       Impact factor: 6.914

Review 2.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 3.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

4.  Effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in proximal and distal pulmonary arterial structure and function.

Authors:  Rebecca R Vanderpool; Ah Ram Kim; Robert Molthen; Naomi C Chesler
Journal:  J Appl Physiol (1985)       Date:  2010-11-18

Review 5.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

Review 6.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

7.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

8.  Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.

Authors:  Lian Tian; Monica Neuber-Hess; Jeffrey Mewburn; Asish Dasgupta; Kimberly Dunham-Snary; Danchen Wu; Kuang-Hueih Chen; Zhigang Hong; Willard W Sharp; Shelby Kutty; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2017-03-06       Impact factor: 4.599

Review 9.  Novel Insights and Treatment Strategies for Right Heart Failure.

Authors:  Weiqin Lin; Ai-Ling Poh; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2018-06

10.  FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate.

Authors:  Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2012-12-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.